Adding a new drug to standard chemotherapy for advanced bile duct cancer
Treatments studied
Part of Cancer clinical trials.
This trial studies whether combining a new drug called ivonescimab with standard chemotherapy works better than the usual chemotherapy and immunotherapy for advanced bile duct cancer. If you qualify, you may receive a treatment that could help shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have been diagnosed with bile duct cancer or gallbladder cancer that has spread or cannot be removed by surgery.
- You have not had chemotherapy for this stage of cancer before.
- You are generally able to take care of yourself (ECOG 0 or 1).
- Your organ function (kidney, liver, blood counts) is within acceptable limits.
- You do not have certain active infections or immune system disorders.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of two chemotherapy drugs (gemcitabine and cisplatin) with an immunotherapy drug (durvalumab), alternating with a targeted therapy (pemigatinib) for people with advanced biliary tract cancer that has an FGFR2 gene change. The goal is to see if this treatment sequence helps control the cancer.
This trial tests a combination of three drugs (ivonescimab, liposomal irinotecan, and 5-FU/LV) to shrink bile duct or gallbladder tumors enough so they can be surgically removed. It is for people who have not had any prior treatment for their cancer.
This trial tests a new drug, ivonescimab, compared to standard chemotherapy (FOLFOX) for people with advanced bile duct cancer that has progressed after initial treatment. It aims to see if ivonescimab can help control the cancer better.
This trial tests a combination of a new immunotherapy drug (cadonilimab) with three chemotherapy drugs for advanced bile duct or gallbladder cancer that has already been treated with gemcitabine. The goal is to see if adding immunotherapy helps control the cancer better.
This trial tests a new immunotherapy drug combined with standard chemotherapy as a first treatment for advanced bile duct or gallbladder cancer. It may help your immune system fight the cancer while chemotherapy attacks the tumor directly.
This trial tests combining immunotherapy (anti-PD-1/PD-L1 antibodies) with standard chemotherapy (gemcitabine and cisplatin) for people with advanced bile duct or gallbladder cancer that can't be removed by surgery. The goal is to see if this combination works better than chemo alone.
Hear when a new Locally Advanced Biliary Tract Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.